SLC5A2 and chronic kidney disease: Chronic kidney disease (CKD) is a worldwide public health issue with a high index of mortality and that despite the newly introduced therapeutic agents to slow the progression of CKD to end‐stage renal disease (ESRD), including SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists [1, 2, 3, 4, 5, 6, 7], there is a residual risk that needs to be targeted and therefore the need to identify novel therapeutic options.